Amarin Corporation

Amarin Corporation R&D per Employee

The R&D Spending per Employee of Amarin Corporation (AMRN) as of Oct 30, 2026 is 247,575.00 USD. In the previous year, R&D Spending per Employee was 260,862.50 USD — a change of -5.09% (lower).

R&D per Employee

247,575.00USD

YoY

-5.09%

Last updated:

R&D Spending per Employee of Amarin Corporation is 2025 247,575.00 USD. R&D Spending per Employee of Amarin Corporation was 2024 260,862.50 USD. It decreases by -5.09% lower compared to the previous year.

The Amarin Corporation R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
698,750.00 USD
Jan 1, 2019
429,900.00 USD
Jan 1, 2020
486,987.50 USD
Jan 1, 2021
366,337.50 USD
Jan 1, 2022
380,137.50 USD
Jan 1, 2023
277,737.50 USD
Jan 1, 2024
260,862.50 USD
Jan 1, 2025
247,575.00 USD
The Amarin Corporation R&D per Employee history
YEARR&D per EmployeeYoY
247,575.00USD-5.09%
260,862.50USD-6.08%
277,737.50USD-26.94%
380,137.50USD+3.77%
366,337.50USD-24.77%
486,987.50USD+13.28%
429,900.00USD-38.48%
698,750.00USD+18.54%
589,475.00USD-5.64%
624,687.50USD-2.13%
638,275.00USD+1.46%
629,075.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

R&D Spending per Employee of Amarin Corporation is 247,575.00 USD in 2025.

R&D Spending per Employee of Amarin Corporation changed from 260,862.50 USD to 247,575.00 USD, representing a -5.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Amarin Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Amarin Corporation

All Key Metrics — Amarin Corporation